Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · IEX Real-Time Price · USD
0.633
-0.034 (-5.17%)
Apr 24, 2024, 3:23 PM EDT - Market open
Company Description
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases.
Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Michael Myers Ph.D. |
Contact Details
Address: 23 Hata'as Street Kfar Saba, L3 44425 Israel | |
| Phone | 97299741444 |
| Website | quoinpharma.com |
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L102 |
| ISIN Number | US74907L3006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
| Gordon Bruce Dunn J.D. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | 8-K | Current Report |
| Apr 3, 2024 | EFFECT | Notice of Effectiveness |
| Apr 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 29, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 424B3 | Prospectus |
| Mar 8, 2024 | 424B3 | Prospectus |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 424B4 | Prospectus |